Press release Archives - PhotoPharmics

PhotoPharmics Announces Publication of Phase 2 Clinical Trial Results in Neurotherapeutics and Its Role in the Company’s Phase 3/Pivotal Clinical Trial

Brett Walker — Tue, 20 Jan 2026 13:00:35 +0000

PhotoPharmics, Inc. today announced the peer-reviewed publication of results from its Phase 2 randomized, double-blind, controlled clinical trial evaluating Celeste®, an investigational photo-neuromodulation device, in people living with Parkinson’s disease (PD). The study has been published in the journal Neurotherapeutics. Celeste® has been designated by the U.S. Food and Drug Administration as a Breakthrough Device.

The publication marks an important scientific milestone for the Company and contributes to the growing body of clinical evidence examining circadian-effective photo-neuromodulation in PD. The Phase 2 findings informed the design of the Company’s ongoing Phase 3/Pivotal trial, which is fully enrolled and expected to complete in Q2 2026.

The Phase 2 study evaluated daily photo-neuromodulation delivered via a patented spectral band of light frequencies designed to engage circadian pathways. The trial assessed both motor and non-motor features in individuals with PD receiving standard-of-care therapies. Celeste was well tolerated over the six-month period, with no serious adverse events reported.

The post PhotoPharmics Announces Publication of Phase 2 Clinical Trial Results in Neurotherapeutics and Its Role in the Company’s Phase 3/Pivotal Clinical Trial appeared first on PhotoPharmics.

PhotoPharmics Announces Board Expansion to Support the Next Phases of Growth: Clinical Execution, Commercialization, and Strategic Partnerships

Brett Walker — Thu, 04 Dec 2025 15:00:59 +0000

The post PhotoPharmics Announces Board Expansion to Support the Next Phases of Growth: Clinical Execution, Commercialization, and Strategic Partnerships appeared first on PhotoPharmics.

PhotoPharmics Surpasses Enrollment Target with 350 Participants in First-of-a-Kind Remote, Home-Based Phase 3 “Light for PD” Clinical Trial

Brett Walker — Wed, 05 Nov 2025 07:00:49 +0000

PhotoPharmics, a clinical-stage medical device company pioneering Photo Neuromodulation for neurodegenerative disease, today announced it has surpassed its enrollment target with 350 participants in its pivotal, Phase 3 Light for PD clinical trial evaluating the Celeste® device for people living with Parkinson’s disease.

“Exceeding our target and closing enrollment is a remarkable milestone for the Parkinson’s community,” said Kent Savage, Chief Executive Officer of PhotoPharmics. “We’re proving that rigorous science can be both patient-centered and home-based. We’re deeply grateful to our investigators, study teams, and especially our participants and their families, whose courage and commitment make this work possible.”

The post PhotoPharmics Surpasses Enrollment Target with 350 Participants in First-of-a-Kind Remote, Home-Based Phase 3 “Light for PD” Clinical Trial appeared first on PhotoPharmics.

PhotoPharmics to Feature Photo Neurostimulation at the 2025 Movement Disorders Society International Congress

Brett Walker — Fri, 03 Oct 2025 14:00:31 +0000

Attendees invited to Booth #732 for pivotal trial updates and to discuss unmet needs in Parkinson’s care PhotoPharmics, a clinical-stage medtech device company specializing in non-invasive photo neurostimulation, today announced its participation in the 2025 International Congress of Parkinson’s Disease and Movement Disorders to be held October 5-9 in Honolulu, Hawaii. The company invites attendees to […]

The post PhotoPharmics to Feature Photo Neurostimulation at the 2025 Movement Disorders Society International Congress appeared first on PhotoPharmics.

PhotoPharmics Forms Commercial Advisory Board to Guide Market Launch of Breakthrough Parkinson’s Therapy

Brett Walker — Thu, 28 Aug 2025 14:00:43 +0000

The post PhotoPharmics Forms Commercial Advisory Board to Guide Market Launch of Breakthrough Parkinson’s Therapy appeared first on PhotoPharmics.

PhotoPharmics Expands Enrollment Beyond 300 in Groundbreaking Trial to Show Improvement Beyond Current Therapies

Brett Walker — Mon, 11 Aug 2025 14:00:28 +0000

New clinical sites open in Illinois, Florida, and Arizona; trial remains open to participants across 19 states. PhotoPharmics, the leader in specialized phototherapy for neurodegenerative diseases, announced today that it is expanding study access to states that have recently added site investigators. Some of these states, like Illinois, Florida, and Arizona, are critical because of […]

The post PhotoPharmics Expands Enrollment Beyond 300 in Groundbreaking Trial to Show Improvement Beyond Current Therapies appeared first on PhotoPharmics.

PhotoPharmics Strengthens Executive Team with Appointments of Samantha John and Greg Schneider

Brett Walker — Wed, 21 May 2025 16:00:29 +0000

The post PhotoPharmics Strengthens Executive Team with Appointments of Samantha John and Greg Schneider appeared first on PhotoPharmics.

PhotoPharmics Closes Oversubscribed $6 Million Series B Extension to Advance FDA Breakthrough Parkinson’s Device

Brett Walker — Fri, 18 Apr 2025 15:43:26 +0000

Original Press Release Funding supports key milestones as the Pivotal, Phase 3 trial surpasses 200 enrolled participants SALT LAKE CITY – PhotoPharmics, a leader in specialized light therapy for neurodegenerative diseases, today announced the close of its oversubscribed $6 million Series B extension. The round was led by Kickstart Fund with participation from current and […]

The post PhotoPharmics Closes Oversubscribed $6 Million Series B Extension to Advance FDA Breakthrough Parkinson’s Device appeared first on PhotoPharmics.

PhotoPharmics Reaches 200 Participants in Landmark Light for PD Clinical Trial

Brett Walker — Mon, 07 Apr 2025 21:13:21 +0000

Two-thirds enrolled in one of the largest remote Parkinson’s trials—redefining access and inclusion in therapeutic research Salt Lake City, Utah – PhotoPharmics announced today that its Pivotal, Phase 3 clinical trial, Light for PD™, has now reached 200 participants—marking two-thirds of its target enrollment. This milestone positions the study as one of the largest remote […]

The post PhotoPharmics Reaches 200 Participants in Landmark Light for PD Clinical Trial appeared first on PhotoPharmics.

PhotoPharmics Announces Leadership Transition in Clinical & Scientific Advisory Board

Brett Walker — Fri, 31 Jan 2025 17:00:00 +0000

PhotoPharmics, a pioneer in specialized phototherapy for neurodegenerative diseases, today announced the appointment of Robert A. Hauser, MD, MBA, as the new Chairman of its Clinical & Scientific Advisory Board (CSAB). Dr. Hauser assumes this leadership role following the recent passing of Warren Olanow, MD, FRCPC, a visionary in the field of Parkinson’s disease research […]

The post PhotoPharmics Announces Leadership Transition in Clinical & Scientific Advisory Board appeared first on PhotoPharmics.